Australia markets open in 6 hours 1 minute
  • ALL ORDS

    7,391.00
    +87.70 (+1.20%)
     
  • AUD/USD

    0.7037
    -0.0012 (-0.17%)
     
  • ASX 200

    7,145.60
    +81.10 (+1.15%)
     
  • OIL

    110.35
    +0.46 (+0.42%)
     
  • GOLD

    1,845.10
    +3.90 (+0.21%)
     
  • BTC-AUD

    42,527.14
    +482.18 (+1.15%)
     
  • CMC Crypto 200

    650.34
    -23.03 (-3.42%)
     

3 Clinical Trials to Watch in the First Half of 2022

·3-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

In this Motley Fool Live video recorded on Jan. 12, 2022, Fool contributors Keith Speights and Brian Orelli discuss three clinical trials especially worth watching in the first half of 2022. Which clinical results are you especially looking forward to seeing? Brian Orelli: Arena (NASDAQ: ARNA), the ticker there is A-R-N-A, it expects data from a phase 3 study of etrasimod in patients with ulcerative colitis.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting